Rituximab in early systemic sclerosis

OBJECTIVES: (1) Hypothesis testing of the potency of rituximab (RTX) in preventing fibrotic complications and (2) assessing acceptability and feasibility of RTX in early systemic sclerosis (SSc). METHODS: A small, 24-month, randomised, double-blind, placebo-controlled, single-centre trial in patient...

詳細記述

保存先:
書誌詳細
出版年:RMD Open
主要な著者: Boonstra, Maaike, Meijs, Jessica, Dorjée, Annemarie L, Marsan, Nina Ajmone, Schouffoer, Anne, Ninaber, Maarten K, Quint, Koen D, Bonte-Mineur, Femke, Huizinga, Tom W J, Scherer, Hans U, de Vries-Bouwstra, Jeska K
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2017
主題:
Systemic Sclerosis
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5574444/
https://ncbi.nlm.nih.gov/pubmed/28879049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000384
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料